Applied DNA Sciences (NASDAQ:APDN), a PCR-based DNA technologies company, announced it will resume its regular quarterly investor call schedule. The company will begin this practice with its fiscal third quarter 2025 financial results release, scheduled for mid-August 2025. As part of this transition, Applied DNA has cancelled its previously planned intra-quarter investor call that was set for June 17, 2025.
Applied DNA Sciences (NASDAQ:APDN), un'azienda specializzata in tecnologie del DNA basate su PCR, ha annunciato che riprenderà il suo consueto calendario trimestrale di chiamate con gli investitori. La società inizierà questa pratica con la pubblicazione dei risultati finanziari del terzo trimestre fiscale 2025, prevista per metà agosto 2025. Nell'ambito di questa transizione, Applied DNA ha annullato la chiamata con gli investitori prevista per il 17 giugno 2025.
Applied DNA Sciences (NASDAQ:APDN), una empresa de tecnologías de ADN basadas en PCR, anunció que reanudará su calendario regular de llamadas trimestrales para inversores. La compañía comenzará esta práctica con la publicación de los resultados financieros del tercer trimestre fiscal de 2025, programada para mediados de agosto de 2025. Como parte de esta transición, Applied DNA ha cancelado la llamada para inversores intra-trimestral que estaba prevista para el 17 de junio de 2025.
Applied DNA Sciences(NASDAQ:APDN)는 PCR 기반 DNA 기술 회사로서 정기 분기별 투자자 전화 회의를 재개할 것이라고 발표했습니다. 회사는 2025 회계연도 3분기 재무 결과 발표를 시작으로 이 관행을 재개할 예정이며, 이는 2025년 8월 중순에 예정되어 있습니다. 이 전환의 일환으로 Applied DNA는 2025년 6월 17일로 예정되어 있던 분기 중 투자자 전화를 취소했습니다.
Applied DNA Sciences (NASDAQ:APDN), une entreprise spécialisée dans les technologies ADN basées sur la PCR, a annoncé qu'elle reprendra son calendrier régulier d'appels trimestriels aux investisseurs. La société commencera cette pratique avec la publication des résultats financiers du troisième trimestre fiscal 2025, prévue pour la mi-août 2025. Dans le cadre de cette transition, Applied DNA a annulé l'appel aux investisseurs intra-trimestriel initialement prévu le 17 juin 2025.
Applied DNA Sciences (NASDAQ:APDN), ein Unternehmen für PCR-basierte DNA-Technologien, hat angekündigt, seinen regulären vierteljährlichen Investorenanrufplan wieder aufzunehmen. Das Unternehmen wird mit der Veröffentlichung der Finanzergebnisse für das dritte Quartal des Geschäftsjahres 2025 beginnen, die für Mitte August 2025 geplant ist. Im Rahmen dieses Übergangs hat Applied DNA den zuvor geplanten Investorenanruf innerhalb des Quartals, der für den 17. Juni 2025 angesetzt war, abgesagt.
Positive
None.
Negative
None.
STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resume a regular quarterly investor call schedule, beginning with the release of its fiscal third quarter 2025 financial results in mid-August 2025. In alignment with this resumption, the Company has cancelled its previously scheduled intra-quarter investor call for June 17, 2025.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.
When will Applied DNA (APDN) report its Q3 2025 financial results?
Applied DNA will report its fiscal third quarter 2025 financial results in mid-August 2025.
Why did Applied DNA cancel its June 17, 2025 investor call?
Applied DNA cancelled its June 17 call as part of its transition to resuming regular quarterly investor calls, with the next call scheduled for mid-August 2025.
What is Applied DNA's (APDN) new investor call schedule?
Applied DNA is resuming a regular quarterly investor call schedule, beginning with its fiscal Q3 2025 results in mid-August 2025.
What type of technology does Applied DNA (APDN) specialize in?
Applied DNA Sciences specializes in PCR-based DNA technologies.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
